Treatments & Services

TGR-1202 in patients with DLBCL, FL, SLL, or MZL

A phase 2b randomized study to assess the efficacy and safety of the combination of Ublituximab + TGR-1202 and TGR-1202 alone in patients with previously treated Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

Disease Types: Lymphoma

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A phase 2b randomized study to assess the efficacy and safety of the combination of Ublituximab + TGR-1202 and TGR-1202 alone in patients with previously treated Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma